Key to the LH trial presentation is slide 4 (NP called it slide 3, maybe not counting cover/title page?) Either way, this slide explains that despite there being no statistical significance as the trial was designed (pre-specified to be analyzed) ... only by analyzing the data in an alternate way using daily data over 8 weeks did they create significance in some symptoms.
By doing so their sample size went from 56 patients to about 3,200 patient-days of data (one patient yields 57 daily data points, day 0-56) for each of the 24 symptoms. ALL statistically significant info presented was part of this 'post-hoc' alternate way to analyze the data that will mean almost nothing to FDA. I doubt they are allowed to analyze Ph3 in this manner.
That said, I believe this way of analyzing the data does enlighten how the next trial should be conducted and analyzed ... which was the main purpose of this small Ph2 trial.